Compare GSL & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSL | EYPT |
|---|---|---|
| Founded | 2007 | 1987 |
| Country | Greece | United States |
| Employees | 11 | N/A |
| Industry | Marine Transportation | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | N/A | 2005 |
| Metric | GSL | EYPT |
|---|---|---|
| Price | $38.87 | $15.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $39.00 | $31.00 |
| AVG Volume (30 Days) | 355.5K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-18-2026 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $965.51 |
| P/E Ratio | $3.49 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.73 | $3.91 |
| 52 Week High | $41.40 | $19.11 |
| Indicator | GSL | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 50.70 | 48.07 |
| Support Level | $35.03 | $11.88 |
| Resistance Level | N/A | $19.06 |
| Average True Range (ATR) | 1.25 | 1.43 |
| MACD | -0.17 | 0.07 |
| Stochastic Oscillator | 43.45 | 50.31 |
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.